Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial
International Journal of Radiation Oncology*Biology*Physics · 2024
DOI: 10.1016/j.ijrobp.2024.05.014 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Diego A S Toesca und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona. Hauptthemen laut MEDLINE: Dose Fractionation, Radiation, Prostate-Specific Antigen, Prostatic Neoplasms, Proton Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: We aimed to determine if ultrahypofractionated proton therapy delivered via stereotactic body proton therapy (SBPT) is noninferior to conventionally fractionated proton therapy (CFPT) in patients with early prostate cancer. METHODS AND MATERIALS: This study was a multicenter, randomized, controlled, noninferiority phase 3 trial that included patients with histologically confirmed low-risk prostate adenocarcinoma defined by Gleason score grouping 1, Prostate-specific antigen
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona.
- Proton Collaborative Group, Warrenville, Illinois; Radiation Oncology Consultants, Elk Grove Village, Illinois.
- Division of Biostatistics, City of Hope, Duarte, California.
- University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
- Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
- Northwestern Medicine Cancer Center Warrenville and Proton Center, Warrenville, Illinois.
Zitieren
APA
Toesca, D. A. S., Hartsell, W. F., DeWees, T. A., Chang, J. H., Laughlin, B. S., Voss, M. M., Dodoo, C. A., Mohammed, N., Keole, S. R., McGee, L. A., Gondi, V., Sweeney, P. J., Dorn, P., Sinesi, C. C., Doh, L. S., Rich, T., & Vargas, C. E. (2024). Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.05.014
Vancouver
Toesca DAS, Hartsell WF, DeWees TA, Chang JH, Laughlin BS, Voss MM, et al. Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.05.014
BibTeX
@article{Toesca2024,
author = {Toesca, Diego A S and Hartsell, William F and DeWees, Todd A and Chang, John H and Laughlin, Brady S and Voss, Molly M and Dodoo, Christopher A and Mohammed, Nasiruddin and Keole, Sameer R and McGee, Lisa A and Gondi, Vinai and Sweeney, Patrick J and Dorn, Paige and Sinesi, Christopher C and Doh, Lucius S and Rich, Tyvin and Vargas, Carlos E},
title = {Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2024},
doi = {10.1016/j.ijrobp.2024.05.014}
}
EUVIMED